By Nick Johnson (Apyx) In 2023 Shareholder News, RenuvionPosted April 28, 2023APYX MEDICAL CORPORATION RECEIVES FDA 510(K) CLEARANCE FOR THE USE OF RENUVION FOR COAGULATION OF SUBCUTANEOUS SOFT TISSUES FOLLOWING LIPOSUCTION FOR AESTHETIC BODY CONTOURING READ MORE
By Nick Johnson (Apyx) In 2023 Shareholder News, J-Plasma, RenuvionPosted April 5, 2023APYX MEDICAL CORPORATION TO RELEASE FIRST QUARTER OF FISCAL YEAR 2023 FINANCIAL RESULTS ON MAY 11, 2023 READ MORE